GA
ALXN

Geneva Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Geneva Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$1.39M Buy
11,408
+82
+0.7% +$9.54K 0.02% 296
2017
Q1 		$1.37M Sell
11,326
-2,030
-15% -$262K 0.02% 285
2016
Q4 		$1.63M Sell
13,356
-165
-1% -$20.2K 0.03% 236
2016
Q3 		$1.66M Sell
13,521
-30
-0.2% -$3.86K 0.03% 227
2016
Q2 		$1.58M Hold
13,551
– – 0.03% 226
2016
Q1 		$1.89M Sell
13,551
-35
-0.3% -$5.14K 0.04% 197
2015
Q4 		$2.59M Sell
13,586
-105
-0.8% -$18.3K 0.05% 161
2015
Q3 		$2.14M Sell
13,691
-462
-3% -$84.3K 0.04% 185
2015
Q2 		$2.56M Buy
14,153
+3,399
+32% +$587K 0.05% 180
2015
Q1 		$1.86M Buy
10,754
+361
+3% +$65.3K 0.03% 214
2014
Q4 		$1.92M Buy
10,393
+228
+2% +$42.2K 0.04% 204
2014
Q3 		$1.69M Sell
10,165
-56
-0.5% -$9.2K 0.03% 213
2014
Q2 		$1.6M Buy
10,221
+1,790
+21% +$283K 0.03% 236
2014
Q1 		$1.28M Buy
8,431
+750
+10% +$119K 0.02% 265
2013
Q4 		$1.02M Sell
7,681
-14
-0.2% -$1.68K 0.02% 255
2013
Q3 		$894K Sell
7,695
-45
-0.6% -$4.94K 0.02% 267
2013
Q2 		$714K Buy
+7,740
New +$746K 0.02% 248

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geneva Advisors's ALXN Position: Q2 2017 in Review

Geneva Advisors increased its Alexion Pharmaceuticals (ALXN) stake by 0.72% in Q2 2017, buying an estimated $9.54K and bringing the position to 11,408 shares worth $1.39M. The position accounts for 0.02% of the portfolio, ranked #296.

Geneva Advisors first reported a position in ALXN in Q2 2013 and has held it in 17 quarters since. The position peaked at $2.59M in Q4 2015. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Geneva Advisors held 11,408 shares of Alexion Pharmaceuticals worth $1.39M as of Q2 2017.
  • Geneva Advisors bought 82 Alexion Pharmaceuticals shares in Q2 2017, an estimated $9.54K.
  • Alexion Pharmaceuticals made up 0.02% of Geneva Advisors's portfolio in Q2 2017, its #296 holding.
  • Geneva Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • Geneva Advisors's Alexion Pharmaceuticals position peaked at $2.59M in Q4 2015.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.